TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03969329: Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of Age With Secondary Hyperparathyroidism and Chron

Sponsor: Amgen · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT03969329 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03969329 Rescue Dossier →